| |
cTACE (n = 174)
|
DEB TACE (n = 76)
| |
|---|
| |
n
|
%
|
n
|
%
|
p
|
|---|
|
Patient demographics
| | | | | |
|
Sex
| | | | |
0.17
|
|
Male
|
144
|
82.8
|
68
|
89.5
| |
|
Female
|
30
|
17.2
|
8
|
10.5
| |
|
Age (years)
| | | | |
0.04
|
|
<60
|
46
|
26.4
|
11
|
14.5
| |
|
≥60
|
128
|
73.6
|
65
|
85.5
| |
|
Etiology of liver cirrhosisa
| | | | | |
|
Alcohol
| | | | |
0.15
|
|
Yes
|
86
|
49.4
|
30
|
39.5
| |
|
No
|
88
|
50.6
|
46
|
60.5
| |
|
HCV
| | | | |
0.91
|
|
Yes
|
47
|
27.0
|
20
|
26.3
| |
|
No
|
127
|
73.0
|
56
|
73.7
| |
|
HBV
| | | | |
0.21
|
|
Yes
|
14
|
8.0
|
10
|
13.2
| |
|
No
|
160
|
92.0
|
66
|
86.8
| |
|
NASH
| | | | |
0.29
|
|
Yes
|
10
|
5.7
|
2
|
2.6
| |
|
No
|
164
|
94.3
|
74
|
97.4
| |
|
Cryptogen
| | | | |
0.01
|
|
Yes
|
5
|
2.9
|
8
|
10.5
| |
|
No
|
169
|
97.1
|
68
|
89.5
| |
|
Prior curative treatment
| | | | |
0.01
|
|
Yes
|
17
|
9.8
|
17
|
22.4
| |
|
No
|
157
|
90.2
|
59
|
77.6
| |
|
Liver function/patient status
| | | | | |
|
BCLC
| | | | |
0.21
|
|
A
|
30
|
17.2
|
8
|
10.5
| |
|
B
|
59
|
33.9
|
34
|
44.7
| |
|
C
|
77
|
44.3
|
30
|
39.5
| |
|
D
|
8
|
4.6
|
4
|
5.3
| |
|
ECOG
| | | | |
0.44
|
|
0
|
110
|
63.2
|
53
|
69.7
| |
|
1
|
61
|
35.1
|
20
|
26.3
| |
|
2
|
2
|
1.1
|
2
|
2.6
| |
|
3
|
1
|
0.6
|
1
|
1.3
| |
|
Portal invasion
| | | | |
0.25
|
|
Yes
|
36
|
20.7
|
11
|
14.5
| |
|
No
|
138
|
79.3
|
65
|
85.5
| |
|
Metastasis
| | | | |
0.66
|
|
Yes
|
5
|
2.9
|
3
|
3.9
| |
|
No
|
169
|
97.1
|
73
|
96.1
| |
|
Child
| | | | |
0.48
|
|
A
|
103
|
59.2
|
51
|
67.1
| |
|
B
|
64
|
36.8
|
22
|
28.9
| |
|
C
|
7
|
4.0
|
3
|
3.9
| |
|
Bilirubin (mg/dl)
| | | | |
0.40
|
|
<2
|
136
|
78.2
|
64
|
84.2
| |
|
2-3
|
24
|
13.8
|
9
|
11.8
| |
|
>3
|
14
|
8.0
|
3
|
3.9
| |
|
Albumin (mg/dl)
| | | | |
0.54
|
|
>3.5
|
76
|
43.7
|
29
|
38.2
| |
|
2.8-3.5
|
67
|
38.5
|
35
|
46.1
| |
|
<2.8
|
31
|
17.8
|
12
|
15.8
| |
|
INR
| | | | |
0.35
|
|
<1.7
|
172
|
98.9
|
76
|
100.0
| |
|
1.7-2.3
|
2
|
1.1
|
0
|
0.0
| |
|
>2.3
|
0
|
0.0
|
0
|
0.0
| |
|
Ascites
| | | | |
0.55
|
|
None
|
118
|
67.8
|
61
|
80.3
| |
|
Mild
|
38
|
21.8
|
11
|
14.5
| |
|
Moderate to severe
|
18
|
10.3
|
4
|
5.3
| |
|
Hepatic encephalopathy
| | | | |
0.26
|
|
None
|
173
|
99.4
|
75
|
98.7
| |
|
Grade I-II
|
1
|
0.6
|
1
|
1.3
| |
|
Grade III-IV
|
0
|
0.0
|
0
|
0.0
| |
|
Tumor characteristics
| | | | | |
|
Tumor grading
| | | | |
0.08
|
|
G1
|
80
|
46.0
|
34
|
44.7
| |
|
G2
|
82
|
47.1
|
30
|
39.5
| |
|
G3
|
12
|
6.9
|
12
|
15.8
| |
|
Milan criteria
| | | | |
0.13
|
|
In
|
47
|
27.0
|
14
|
18.4
| |
|
Out
|
127
|
73.0
|
62
|
81.6
| |
|
SLD (cm)
| | | | |
0.93
|
|
<3
|
19
|
10.9
|
8
|
10.5
| |
|
≥3
|
155
|
89.1
|
68
|
89.5
| |
- HBV hepatitis B virus, HCV hepatitis C virus, NASH nonalcoholic steatohepatitis, BCLC barcelona clinic liver cancer classification, ECOG eastern cooperative oncology group, INR international normalized ratio, SLD sum of the longest diameter
- a5 patients with HBV/HCV co-infection
